Search results for "very"

showing 10 items of 6927 documents

Cytotoxicity of Labruscol, a New Resveratrol Dimer Produced by Grapevine Cell Suspensions, on Human Skin Melanoma Cancer Cell Line HT-144

2017

IF 2.861; International audience; A new resveratrol dimer (1) called labruscol, has been purified by centrifugal partition chromatography of a crude ethyl acetate stilbene extract obtained from elicited grapevine cell suspensions of Vitis labrusca L. cultured in a 14-liter stirred bioreactor. One dimensional (1D) and two dimensional (2D) nuclear magnetic resonance (NMR) analyses including ¹H, 13C, heteronuclear single-quantum correlation (HSQC), heteronuclear multiple bond correlation (HMBC), and correlation spectroscopy (COSY) as well as high-resolution electrospray ionisation mass spectrometry (HR-ESI-MS) were used to characterize this compound and to unambiguously identify it as a new st…

0301 basic medicineMagnetic Resonance SpectroscopySkin NeoplasmsCellPharmaceutical ScienceApoptosisResveratrolresveratrol[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyAnalytical Chemistry[ SDV.CAN ] Life Sciences [q-bio]/Cancerchemistry.chemical_compoundbioreactor0302 clinical medicineBioreactorsDrug DiscoveryStilbenesVitisCytotoxicitylabruscolMolecular StructureChemistryCommunicationVitis labrusca L.Biological activity3. Good healthmedicine.anatomical_structureBiochemistryChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineDimerizationCell Survivallcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryCell Line TumorPlant CellsfibroblastsmedicinemelanomaHumansViability assayPhysical and Theoretical Chemistrycytotoxic activityOrganic Chemistry[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyAntineoplastic Agents Phytogenic030104 developmental biologyApoptosisCell cultureFetal bovine serum
researchProduct

Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals.

2016

While changes in gut microbial populations have been described in human immuno-deficiency virus (HIV)-infected patients undergoing antiretroviral therapy (ART), the mechanisms underlying the contributions of gut bacteria and their molecular agents (metabolites and proteins) to immune recovery remain unexplored. To study this, we examined the active fraction of the gut microbiome, through examining protein synthesis and accumulation of metabolites inside gut bacteria and in the bloodstream, in 8 healthy controls and 29 HIV-infected individuals (6 being longitudinally studied). We found that HIV infection is associated to dramatic changes in the active set of gut bacteria simultaneously alter…

0301 basic medicineMale030106 microbiologylcsh:MedicineInflammationHIV InfectionsGut microbiotaGut floraGeneral Biochemistry Genetics and Molecular BiologyVirusMicrobiology03 medical and health sciencesMedicine General & InternalImmunityAntiretroviral Therapy Highly ActivemedicineMetabolomeHumansMetabolomicsImmune recoveryBiologyMetaproteomelcsh:R5-920biologyBacteriaGastrointestinal Microbiomelcsh:RImmunityHIVGeneral MedicineViral Loadbiology.organism_classificationCD4 Lymphocyte CountGastrointestinal MicrobiomeAntiretroviral therapy030104 developmental biologyCase-Control StudiesImmunologyHIV-1MetabolomeFemalemedicine.symptomlcsh:Medicine (General)Viral loadBacteriaBiomarkersResearch PaperEBioMedicine
researchProduct

Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients

2019

<b><i>Background:</i></b> Dexrazoxane (DEX) is indicated as a cardioprotective agent for breast cancer patients receiving the anthracycline doxorubicin. Two meta-analyses in metastatic breast cancer reported an apparent increase in the severity of myelosuppression when DEX was used. So far, no data in soft-tissue sarcoma (STS) patients are available. <b><i>Methods:</i></b> We retrospectively analyzed hematological toxicity data from 133 consecutive STS patients who received a chemotherapy regimen containing an anthracycline and ifosfamide (AI) in the perioperative or metastatic settings between January 2006 and December 2017. Of these, 46 rece…

0301 basic medicineMaleAnthracyclineGastroenterology0302 clinical medicineMyelotoxicityRetrospective StudieDrug DiscoveryMedicinePharmacology (medical)AnthracyclinesSoft tissue sarcomaLeukopeniaIfosfamideAntibiotics AntineoplasticSarcomaGeneral MedicineMiddle AgedChemotherapy regimenInfectious DiseasesOncologyBone marrow suppression030220 oncology & carcinogenesisFemalemedicine.symptommedicine.drugHumanAdultmedicine.medical_specialtyNeutropeniaAnthracycline030106 microbiologyNeutropeniaProtective Agents03 medical and health sciencesYoung AdultInternal medicineHumansDexrazoxaneProtective AgentRetrospective StudiesAgedPharmacologybusiness.industryHematologic Diseasemedicine.diseaseHematologic DiseasesDexrazoxanebusinessFebrile neutropenia
researchProduct

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

2016

The potential of bispecific T cell-engaging antibodies is hindered by manufacturing challenges and short serum half-life. We circumvented these limitations by treating mice with in vitro-transcribed pharmacologically optimized, nucleoside-modified mRNA encoding the antibody. We achieved sustained endogenous synthesis of the antibody, which eliminated advanced tumors as effectively as the corresponding purified bispecific antibody. Because manufacturing of pharmaceutical mRNA is fast, this approach could accelerate the clinical development of novel bispecific antibodies.

0301 basic medicineMaleBispecific antibodyT-LymphocytesImmunoblottingEndogenyEnzyme-Linked Immunosorbent AssayIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesMiceMice Inbred NODCell Line TumorNeoplasmsAntibodies BispecificMedicineAnimalsHumansRNA MessengerMessenger RNAMice Inbred BALB Cbiologybusiness.industryRNAGeneral MedicineMolecular biologyImmunohistochemistryXenograft Model Antitumor AssaysTumor Burden030104 developmental biologyCell cultureDrug deliveryLuminescent Measurementsbiology.proteinImmunohistochemistryCytokinesFemaleAntibodybusinessNature medicine
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Treatment with albumin-hydroxyoleic acid complex restores sensorimotor function in rats with spinal cord injury: Efficacy and gene expression regulat…

2017

Sensorimotor dysfunction following incomplete spinal cord injury (SCI) is often characterized by paralysis, spasticity and pain. Previously, we showed that intrathecal (i.t.) administration of the albumin-oleic acid (A-OA) complex in rats with SCI produced partial improvement of these symptoms and that oral 2-hydroxyoleic acid (HOA, a non-hydrolyzable OA analogue), was efficacious in the modulation and treatment of nociception and pain-related anxiety, respectively. Here we observed that intrathecal treatment with the complex albumin-HOA (A-HOA) every 3 days following T9 spinal contusion injury improved locomotor function assessed with the Rotarod and inhibited TA noxious reflex activity in…

0301 basic medicineMaleNociceptionCritical Care and Emergency Medicinelcsh:MedicineGene ExpressionOleic AcidsPharmacologyProstaglandin E synthaseImmune ReceptorsBiochemistry0302 clinical medicineCell SignalingMedicine and Health SciencesMembrane Receptor Signalinglcsh:ScienceSpinal Cord InjurySpinal cord injuryToll-like ReceptorsTrauma MedicineInjections SpinalProstaglandin-E SynthasesExtracellular Matrix ProteinsMultidisciplinaryImmune System ProteinsbiologyTenascin CTenascinComplement ReceptorsImmune Receptor SignalingNociceptionTreatment OutcomeNeurologySpinal CordPhospholipasesmedicine.symptomTraumatic InjuryLocomotionResearch ArticleSignal TransductionTransmembrane ReceptorsImmunologyPainInflammationNerve Tissue ProteinsGrowth Differentiation Factor 10Drug Administration Schedule03 medical and health sciencesAlbuminsmedicineGeneticsAnimalsParalysisSpasticityRats WistarSpinal Cord Injuriesbusiness.industrylcsh:RBiology and Life SciencesProteinsCell BiologyRecovery of Functionmedicine.diseaseNeuroregenerationRats030104 developmental biologyGene Expression RegulationGDF10Rotarod Performance Testbiology.proteinlcsh:QbusinessNeurotrauma030217 neurology & neurosurgeryPLoS ONE
researchProduct

Case-control study on intestinal intussusception: implications for anti-rotavirus vaccination.

2018

Background: Intussusception represents the most common cause of abdominal emergency among young children but nearly 75% of cases are still considered idiopathic. Research design and methods: A case–control study was conducted among Sicilian children aged 0–59 months with a hospital admission for intussusception between 2009 and 2015 to identify factors associated with intussusception onset. Results: Overall, 125 cases and 190 controls were recruited for the study. Birth order (OR 1.49, 95%CI: 1.10, 2.02, P = 0.02) and having had gastroenteritis or having taken antibiotics during the 30 days prior to hospitalization (OR 11.55, 95%CI: 3.23, 41.23, P < 0.001; 3.09, 95%CI: 1.17, 8.12, P = 0.009…

0301 basic medicineMalePediatricsmedicine.medical_specialtyanti-rotavirus vaccinebreastfeeding030106 microbiologyImmunologyBreastfeedingRotavirus vaccination03 medical and health sciences0302 clinical medicineRisk Factors030225 pediatricsIntussusception (medical disorder)Drug DiscoverymedicineHumansRisk factorAntibiotic useSicilyPharmacologybusiness.industryDrug Discovery3003 Pharmaceutical ScienceCase-control studyInfant NewbornRotavirus VaccinesInfantProtective Factorsmedicine.diseaseAnti-Bacterial AgentsGastroenteritisHospitalizationBreast Feedingrisk factorCase-Control StudiesChild PreschoolAntibiotic useMolecular MedicineIntestinal intussusceptionFemalegastroenteritiBirth OrderbusinessIntussusceptionExpert review of vaccines
researchProduct

Effects of nifedipine on renal and cardiovascular responses to neuropeptide y in anesthetized rats

2021

Neuropeptide Y (NPY) acts via multiple receptor subtypes termed Y1, Y2 and Y5. While Y1 receptor-mediated effects, e.g., in the vasculature, are often sensitive to inhibitors of L-type Ca2+ channels such as nifedipine, little is known about the role of such channels in Y5-mediated effects such as diuresis and natriuresis. Therefore, we explored whether nifedipine affects NPY-induced diuresis and natriuresis. After pre-treatment with nifedipine or vehicle, anesthetized rats received infusions or bolus injections of NPY. Infusion NPY (1 µg/kg/min) increased diuresis and natriuresis, and this was attenuated by intraperitoneal injection of nifedipine (3 µg/kg). Concomitant decreases in heart ra…

0301 basic medicineMaleReceptors Neuropeptidemedicine.medical_treatmentMedizinPharmaceutical ScienceOrganic chemistry030204 cardiovascular system & hematologyAnalytical ChemistryReceptors G-Protein-CoupledY<sub>1</sub> receptor0302 clinical medicineBolus (medicine)QD241-441Drug DiscoveryMedicineY1 receptorblood pressureNeuropeptide Y receptorCalcium Channel Blockershumanitiesnifedipinemedicine.anatomical_structureChemistry (miscellaneous)Molecular MedicineY5 receptormedicine.drugmedicine.medical_specialtyneuropeptide YIntraperitoneal injectionnatriuresisDiuresisArticleNatriuresis03 medical and health sciencesY<sub>5</sub> receptorNifedipineInternal medicinemental disordersAnimalsPhysical and Theoretical ChemistryRats Wistarbusiness.industryrenal blood flowRatsReceptors Neuropeptide Ydiuresis030104 developmental biologyEndocrinologyRenal blood flowVascular resistancebusiness
researchProduct

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

2019

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility…

0301 basic medicineMaleStreptococcus pneumoniaantibiotic resistanceInternationalitysputum examinationbronchiectasisvery elderlyAntibioticsPrevalenceDrug resistancemedicine.disease_causeLogistic regressionGlobal HealthCommunity-Acquired Infections/epidemiologylung lavage0302 clinical medicineCommunity-acquired pneumoniaCost of IllnessRisk FactorsPrevalencedrug resistant Streptococcus pneumoniae pneumonia030212 general & internal medicineMicrobial drug resistantAged 80 and overadultinternational cooperationdrug effectMiddle Agedinfluenza vaccinationAnti-Bacterial Agentsantiinfective agentEuropeCommunity-Acquired InfectionsHospitalizationGlobal burden of diseaseStreptococcus pneumoniaeInfectious Diseasesrisk factorbacterium identificationFemalecommunity acquired infectioninfluenzaliver diseasepneumococcal vaccinationPneumococcal infectionhospitalizationmedicine.drugMicrobiology (medical)medicine.medical_specialtyAsiamedicine.drug_class030106 microbiologySettore MED/10 - Malattie Dell'Apparato RespiratorioArticleAnti-Bacterial Agents/pharmacology03 medical and health sciencesInternal medicineStreptococcus pneumoniaeDrug Resistance BacterialPneumonia Pneumococcal/epidemiologymedicineHumanscontrolled studyhumantetracyclineHospitalization/statistics & numerical dataAgedlevofloxacinnonhumanbusiness.industrydisease associationmicrobiologycommunity acquired pneumoniamacrolidePneumoniaasthmaSouth AmericaPneumonia Pneumococcalvaccinationmedicine.diseasemajor clinical studyantibiotic sensitivitypenicillin derivativePenicillinStreptococcus pneumoniae/drug effectsPneumoniablood examinationAfricaNorth Americamicrobiological examinationbusinessGlobal burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia
researchProduct

Effects of transcranial random noise stimulation combined with Graded Repetitive Arm Supplementary Program (GRASP) on motor rehabilitation of the upp…

2019

We evaluated the combined use of transcranial random noise stimulation (tRNS) with the Graded Repetitive Arm Supplementary Program (GRASP) in sub-acute ischemic stroke patients suffering from arm impairment. Eighteen ischemic stroke patients with upper limb disability were randomly assigned to either the GRASP + tRNS or GRASP + Sham stimulation group. Fugl-Meyer Assessment-Upper extremity (FMA-UE) was performed to evaluate upper limb impairment before treatment (T0), after the last stimulation (T1) and after 30 days (T2). At T1 and T2, beneficial effects in the tRNS group correlated with better FMA-UE score than sham stimulation group (p &lt; 0.001) and these results did not correlate to st…

0301 basic medicineMaleStroke rehabilitationmedicine.medical_specialtyNeurologyStimulationPilot ProjectsSub acuteTranscranial Direct Current StimulationUpper Extremity03 medical and health sciencesTranscranial random noise stimulation0302 clinical medicinePhysical medicine and rehabilitationDouble-Blind MethodmedicineHumansGraded Repetitive Arm Supplementary Program (Grasp)Biological PsychiatryPhysical Therapy ModalitiesAgedbusiness.industryGRASPTranscranial random noise stimulation combined (tRNS)BrainRecovery of FunctionCombined Modality TherapyMotor rehabilitationPsychiatry and Mental health030104 developmental biologymedicine.anatomical_structureTreatment OutcomeNeurologyIschemic strokeUpper limbFemaleSettore MED/26 - NeurologiaNeurology (clinical)business030217 neurology & neurosurgery
researchProduct